JAAD Examines Lymphoma Risk Signals in Hidradenitis Suppurativa
JAAD published online October 17, 2026 an analysis by Islam, Islam and Wu on interpreting lymphoma risk in hidradenitis suppurativa and its clinical practice implications.
Topic
Hidradenitis Suppurativa
Topic
Hidradenitis Suppurativa
Luis Garza, M.D., Ph.D., on What Hidradenitis Suppurativa Is Not
Luis Garza, M.D., Ph.D., defines hidradenitis suppurativa by its misconceptions in a new interview — a corrective aimed at the di…
JAAD Publishes Framework to Make HS Lymphoma Risk Actionable
Published online 16 October 2026 in JAAD, Wang and Fan's paper aims to turn known lymphoma risk in hidradenitis suppurativa into…
International Cost Comparison Puts HS Biologics Under the Microscope
A new international comparison examines cost efficiency of biologic therapies for hidradenitis suppurativa, with direct implicati…
Outpatient Derm Visits Tied to Fewer HS Hospital Readmissions
Patients with hidradenitis suppurativa who maintain outpatient dermatology care show fewer hospital readmissions, new findings su…
UCB Launches 'Wear It Out' Campaign for HS, Psoriasis, and PsA
UCB has launched 'Wear It Out,' a patient-facing campaign aimed at people living with hidradenitis suppurativa, plaque psoriasis,…
HS Experts Talk Expectations and Comorbidities in New Video
A Fall Clinical expert video tackles two hard parts of hidradenitis suppurativa care: patient expectations and the comorbidities…
Are We Missing Hidradenitis Suppurativa in Men?
Clinicians writing for HCPLive are asking whether hidradenitis suppurativa is systematically underdiagnosed in men, a question wi…
Escalating HS Therapy After Biologic Failure: Dermatology Times Case 2
Dermatology Times' Case 2 examines escalation strategy after biologic failure in hidradenitis suppurativa, where approved options…
Distinguishing HS Flares From Loss of Treatment Response
HS lacks a validated tool for distinguishing true inflammatory flares from progressive loss of biologic response, leaving treatme…